by GL Bakris 2024 Cited by 616ESRD or death were summarized between the 2 treatment groups. The risk reduction of losartan compared with placebo for ESRD alone and for ESRD or death was
by A Arredondo 2024 Cited by 11Results. The projected lifetime incidence of ESRD for losartan patients was lower (66%) compared with placebo patients (83%). This reduction in ESRD resulted in
losartan on renal and cardiovascular outcomes in patients with end-stage renal disease (ESRD), or death. The secondary outcome was
Losartan significantly reduced the risk for the combined endpoint of end-stage renal disease (ESRD), MI, stroke, or death by 21% (p 0.005), irrespective of whether all-cause or cardiovascular death was included in the analysis. In addition, losartan reduced the risk for the composite of ESRD or cardiovascular death by 19.2% (p 0.05).
Losartan potassium . subjects with ESRD on haemodialysis. The Cmax of canagliflozin was increased by 13%, 29%, and 29% in subjects with mild, moderate
by A Arredondo 2024 Cited by 11Results. The projected lifetime incidence of ESRD for losartan patients was lower (66%) compared with placebo patients (83%). This reduction in ESRD resulted in
Losartan reduced the incidence of doubling of serum creatinine, end-stage renal disease (ESRD), or death by 16% (P = 0.022) and reduced the risk of progression to ESRD, defined as the initiation of dialysis or transplantation, by 29% (P = 0.002).
in common use in populations with renal failure and end-stage renal disease (ESRD). Objective: To investigate the pharmacokinetics and pharmacodynamics of losartan in patients with ESRD in order to establish administration guidelines. Methods: Patients were administered losartan 100 mg/day for 7 days, and after
ESRD มีข้อมูลพบว่าการให้ ACEI or ARB ช่วย preserve residual renal losartan คาดว่าไม่น่าจะส่งผลให้เกิด urate nephropathy มากขึ้นหรือ
Comments